AMAG Pharmaceuticals, Inc. (AMAG)
AMAG Price and Sentiment
AMAG Latest news
AMAG Pharmaceuticals Files Submission in Response To the Food And Drug Administration's Notice of Opportunity for a Hearing and Proposal To Withdraw Approval of Makena® (hydroxyprogesterone caproate injection)
2020-12-14 08:47WALTHAM, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. has submitted its response to the FDA's Notice of Opportunity for a Hearing (“NOOH”) regarding the Agency's proposal to withdraw approval for Makena—also referred to as 17-OHPC—the only FDA-approved treatment, along with five generic versions, to reduce preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Contango Oil & Gas Company, Eaton Vance Corp., MobileIron, Inc., Seacoast Commerce Banc Holdings, Perceptron, Inc., Standard AVB Financial Corp., Virginia National Bankshares C
2020-11-04 19:31NEW YORK, Nov. 4, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would...
AMAG Pharmaceuticals (AMAG) Earnings Expected to Grow: Should You Buy?
2020-10-30 12:30AMAG Pharmaceuticals (AMAG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Lifshitz Law Firm, P.C. Announces Investigation of AMAG Pharmaceuticals, Inc., Eaton Vance Corp., MobileIron, Inc., Seacoast Commerce Banc Holdings, Perceptron, Inc., Standard AVB Financial Corp., Virginia National Bankshares Corporation and Virtusa Corpo
2020-10-20 18:13NEW YORK, Oct. 20, 2020 /PRNewswire/ -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AMAG to Covis Group S.à r.l. for $13.75 per share. If you are a AMAG investor, and would...
Covis Group S.à r.l. Announces Commencement of Tender Offer for All Outstanding Shares of AMAG Pharmaceuticals, Inc.
2020-10-15 07:30LUXEMBOURG and ZUG, Switzerland, Oct. 15, 2020 /PRNewswire/ -- Covis Group S.à r.l. ("Covis") announced the commencement of a cash tender offer to purchase all of the outstanding shares of common stock of AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) ("AMAG"). The tender offer is being made...
AMAG Pharmaceuticals Requests Hearing to Maintain Makena® (Hydroxyprogesterone Caproate Injection) as a Treatment Option for Clinically Indicated Pregnant Patients
2020-10-14 16:11WALTHAM, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it has formally requested a public hearing in response to the U.S. Food and Drug Administration’s (FDA) proposal to withdraw its approval of Makena®, the only FDA-approved treatment, along with its equivalent generics, to reduce preterm birth. Makena was approved in 2011, based on the landmark NICHD MFMU trial by Meis et al. A second, FDA-required trial (PROLONG) predominantly enrolled women outside of the U.S., in countries with markedly lower rates of preterm birth. The PROLONG trial did not show a difference between treatment and vehicle arms with respect to preterm birth or neonatal outcome. However, maternal and fetal safety was re-affirmed.
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of AMAG Pharmaceuticals, Inc. - AMAG
2020-10-09 17:44NEW YORK, Oct. 9, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating AMAG Pharmaceuticals, Inc. ("AMAG" or the "Company") (AMAG) relating...
AMAG PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AMAG Pharmaceuticals, Inc. - AMAG
2020-10-09 14:24NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of AMAG Pharmaceuticals, Inc. (NasdaqGS: AMAG) to Covis Group S.à.r.l. Under the terms of the proposed transaction, shareholders of AMAG will receive only $13.75 in cash for each share of AMAG that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whe
ALERT: Halper Sadeh LLP Continues to Investigate the Following Mergers; Shareholders are Encouraged to Contact the Firm - AMAG, SBPH, VAR, SINA, GARS
2020-10-05 23:07NEW YORK, Oct. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating: AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Covis Group...
AMAG Pharmaceuticals Provides Update on FDA’s Proposal Regarding Makena® (Hydroxyprogesterone Caproate Injection)
2020-10-05 21:05WALTHAM, Mass., Oct. 05, 2020 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) announced today that it received a notice from the U.S. Food and Drug Administration (FDA) that the FDA is proposing to withdraw approval of Makena® (hydroxyprogesterone caproate injection), a treatment approved to reduce preterm birth in pregnant women who have had a prior spontaneous preterm birth. The FDA in its letter also notified AMAG that the company has the opportunity to request a hearing on the withdrawal.